Navigation Links
Perrigo Company Will Release Third Quarter Fiscal 2008 Results on May 6, 2008

ALLEGAN, Mich., April 23 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it will release financial results for its third quarter fiscal 2008 on Tuesday, May 6, 2008 at approximately 8:00 a.m. (ET). The Company will conduct a conference call at 10:00 a.m. (ET) hosted by Joseph C. Papa, Perrigo's Chairman and Chief Executive Officer.

The conference call will be available live via webcast to interested parties on the Perrigo website or by phone 888-694-4676, International 973-582-2737, and reference ID# 44342528. A taped replay of the call will be available beginning at approximately 2:30 p.m. (ET) Tuesday, May 6, until midnight Tuesday, May 13, 2008. To listen to the replay, call 800-642-1687, International 706-645-9291, access code 44342528.

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing facilities are the United States, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (

SOURCE Perrigo Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Perrigo Confirms Patent Challenge of Monistat(R) 1 Combination Pack
2. Perrigo Company to Present at the 12th Annual Sidoti Emerging Growth Institutional Investor Forum
3. Perrigo Company Announces Launch of Clobetasol Propionate Foam
4. Perrigo Company Receives Final Approval on Clobetasol Propionate Foam
5. Perrigo Company to Market Over-the-Counter Cetirizine Hydrochloride, Pseudoephedrine Hydrochloride Extended-Release Tablets
6. Perrigo Company Announces Initial Shipments of Store Brand Omeprazole Tablets
7. Perrigo Company Announces Final FDA Approval for OTC Famotidine Complete Chewable Tablets
8. Perrigo Company Authorizes Continuation of Share Repurchase Program and Announces Quarterly Dividend
9. Perrigo Acquires UK OTC Store Brand Supplier
10. Perrigo Company to Present at The 26th Annual JPMorgan Healthcare Conference
11. Perrigo Announces that Dexcels Settlement with AstraZeneca Allows OTC Omeprazole Launch Following Final FDA Approval
Post Your Comments:
(Date:11/27/2015)... ... ... No.1 Herpes-only dating community in the world, revealed that over 50% of its members are ... people under the age of 50 – or 67% of the population - are infected ... HSV-1 infection . , "The data shocks us highly!" said Michelle Li, Co-Founder of ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping ... platform for mental health and wellness consultation, has collaborated with a leading web-based ... the knowledge gap experienced by parents and bring advice from parenting experts within ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer and ... of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. ... 5.10 up-to-date with a version of Asterisk that will receive not only security ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent ... and the need to integrate dose form selection in early phase drug development. ... membership organization supporting and bringing together the UK’s emerging life sciences companies, corporate ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... and wellness consultation, has collaborated with Women’s Web – an online resource ... on topics on mental and emotional well-being relationship, life balance, stress, professional ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... to their offering. --> Research and ... of the "Self Administration of High Viscosity ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the European Cell Surface Marker Testing ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
(Date:11/25/2015)... 25, 2015  Amgen (NASDAQ: AMGN ) today ... with the United States (U.S.) ... biosimilar candidate to Humira ® (adalimumab). Amgen believes ... to the FDA and represents Amgen,s first BLA submission ... Harper , M.D., executive vice president of Research and ...
Breaking Medicine Technology: